vs

Side-by-side financial comparison of Dexcom (DXCM) and Marvell Technology, Inc. (MRVL). Click either name above to swap in a different company.

Marvell Technology, Inc. is the larger business by last-quarter revenue ($2.1B vs $1.3B, roughly 1.6× Dexcom). Marvell Technology, Inc. runs the higher net margin — 91.7% vs 21.2%, a 70.4% gap on every dollar of revenue. On growth, Marvell Technology, Inc. posted the faster year-over-year revenue change (36.8% vs 21.6%). Over the past eight quarters, Marvell Technology, Inc.'s revenue compounded faster (20.6% CAGR vs 12.0%).

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

Marvell Technology, Inc. is an American company, headquartered in Santa Clara, California, which develops and produces semiconductors and related technology. Founded in 1995, the company had more than 6,500 employees as of 2024, with over 10,000 patents worldwide, and an annual revenue of $5.5 billion for fiscal 2024.

DXCM vs MRVL — Head-to-Head

Bigger by revenue
MRVL
MRVL
1.6× larger
MRVL
$2.1B
$1.3B
DXCM
Growing faster (revenue YoY)
MRVL
MRVL
+15.2% gap
MRVL
36.8%
21.6%
DXCM
Higher net margin
MRVL
MRVL
70.4% more per $
MRVL
91.7%
21.2%
DXCM
Faster 2-yr revenue CAGR
MRVL
MRVL
Annualised
MRVL
20.6%
12.0%
DXCM

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
DXCM
DXCM
MRVL
MRVL
Revenue
$1.3B
$2.1B
Net Profit
$267.3M
$1.9B
Gross Margin
62.9%
51.6%
Operating Margin
25.6%
17.2%
Net Margin
21.2%
91.7%
Revenue YoY
21.6%
36.8%
Net Profit YoY
153.6%
381.1%
EPS (diluted)
$0.67
$2.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DXCM
DXCM
MRVL
MRVL
Q1 26
$1.3B
Q4 25
$1.3B
$2.1B
Q3 25
$1.2B
$2.0B
Q2 25
$1.2B
$1.9B
Q1 25
$1.0B
$1.8B
Q4 24
$1.1B
$1.5B
Q3 24
$994.2M
$1.3B
Q2 24
$1.0B
$1.2B
Net Profit
DXCM
DXCM
MRVL
MRVL
Q1 26
$267.3M
Q4 25
$267.3M
$1.9B
Q3 25
$283.8M
$194.8M
Q2 25
$179.8M
$177.9M
Q1 25
$105.4M
$200.2M
Q4 24
$151.7M
$-676.3M
Q3 24
$134.6M
$-193.3M
Q2 24
$143.5M
$-215.6M
Gross Margin
DXCM
DXCM
MRVL
MRVL
Q1 26
62.9%
Q4 25
62.9%
51.6%
Q3 25
60.5%
50.4%
Q2 25
59.5%
50.3%
Q1 25
56.9%
50.5%
Q4 24
58.9%
23.0%
Q3 24
59.7%
46.2%
Q2 24
62.4%
45.5%
Operating Margin
DXCM
DXCM
MRVL
MRVL
Q1 26
25.6%
Q4 25
25.6%
17.2%
Q3 25
20.1%
14.5%
Q2 25
18.4%
14.3%
Q1 25
12.9%
12.9%
Q4 24
17.0%
-46.4%
Q3 24
15.3%
-7.9%
Q2 24
15.7%
-13.1%
Net Margin
DXCM
DXCM
MRVL
MRVL
Q1 26
21.2%
Q4 25
21.2%
91.7%
Q3 25
23.5%
9.7%
Q2 25
15.5%
9.4%
Q1 25
10.2%
11.0%
Q4 24
13.6%
-44.6%
Q3 24
13.5%
-15.2%
Q2 24
14.3%
-18.6%
EPS (diluted)
DXCM
DXCM
MRVL
MRVL
Q1 26
$0.67
Q4 25
$0.67
$2.20
Q3 25
$0.70
$0.22
Q2 25
$0.45
$0.20
Q1 25
$0.27
$0.23
Q4 24
$0.37
$-0.78
Q3 24
$0.34
$-0.22
Q2 24
$0.35
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DXCM
DXCM
MRVL
MRVL
Cash + ST InvestmentsLiquidity on hand
$917.7M
$2.7B
Total DebtLower is stronger
$4.5B
Stockholders' EquityBook value
$2.7B
$14.1B
Total Assets
$6.3B
$21.6B
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DXCM
DXCM
MRVL
MRVL
Q1 26
$917.7M
Q4 25
$917.7M
$2.7B
Q3 25
$1.8B
$1.2B
Q2 25
$1.2B
$885.9M
Q1 25
$904.9M
$948.3M
Q4 24
$606.1M
$868.1M
Q3 24
$621.2M
$808.7M
Q2 24
$939.2M
$847.7M
Total Debt
DXCM
DXCM
MRVL
MRVL
Q1 26
Q4 25
$4.5B
Q3 25
$4.5B
Q2 25
$4.2B
Q1 25
$4.1B
Q4 24
$4.1B
Q3 24
$4.1B
Q2 24
$4.1B
Stockholders' Equity
DXCM
DXCM
MRVL
MRVL
Q1 26
$2.7B
Q4 25
$2.7B
$14.1B
Q3 25
$2.7B
$13.4B
Q2 25
$2.6B
$13.3B
Q1 25
$2.3B
$13.4B
Q4 24
$2.1B
$13.4B
Q3 24
$2.0B
$14.2B
Q2 24
$2.4B
$14.5B
Total Assets
DXCM
DXCM
MRVL
MRVL
Q1 26
$6.3B
Q4 25
$6.3B
$21.6B
Q3 25
$7.5B
$20.6B
Q2 25
$7.3B
$20.0B
Q1 25
$6.8B
$20.2B
Q4 24
$6.5B
$19.7B
Q3 24
$6.4B
$20.3B
Q2 24
$6.8B
$20.5B
Debt / Equity
DXCM
DXCM
MRVL
MRVL
Q1 26
Q4 25
0.32×
Q3 25
0.33×
Q2 25
0.32×
Q1 25
0.30×
Q4 24
0.31×
Q3 24
0.29×
Q2 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DXCM
DXCM
MRVL
MRVL
Operating Cash FlowLast quarter
$582.3M
Free Cash FlowOCF − Capex
$508.8M
FCF MarginFCF / Revenue
24.5%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
0.31×
TTM Free Cash FlowTrailing 4 quarters
$1.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DXCM
DXCM
MRVL
MRVL
Q1 26
Q4 25
$294.0M
$582.3M
Q3 25
$659.9M
$461.6M
Q2 25
$303.0M
$332.9M
Q1 25
$183.8M
$514.0M
Q4 24
$301.4M
$536.3M
Q3 24
$199.5M
$306.4M
Q2 24
$279.4M
$324.5M
Free Cash Flow
DXCM
DXCM
MRVL
MRVL
Q1 26
Q4 25
$192.1M
$508.8M
Q3 25
$579.4M
$414.1M
Q2 25
$208.9M
$214.1M
Q1 25
$96.8M
$444.1M
Q4 24
$176.8M
$461.3M
Q3 24
$88.3M
$258.2M
Q2 24
$213.3M
$233.0M
FCF Margin
DXCM
DXCM
MRVL
MRVL
Q1 26
Q4 25
15.3%
24.5%
Q3 25
47.9%
20.6%
Q2 25
18.1%
11.3%
Q1 25
9.3%
24.4%
Q4 24
15.9%
30.4%
Q3 24
8.9%
20.3%
Q2 24
21.2%
20.1%
Capex Intensity
DXCM
DXCM
MRVL
MRVL
Q1 26
Q4 25
8.1%
3.5%
Q3 25
6.7%
2.4%
Q2 25
8.1%
6.3%
Q1 25
8.4%
3.8%
Q4 24
11.2%
4.9%
Q3 24
11.2%
3.8%
Q2 24
6.6%
7.9%
Cash Conversion
DXCM
DXCM
MRVL
MRVL
Q1 26
Q4 25
1.10×
0.31×
Q3 25
2.33×
2.37×
Q2 25
1.69×
1.87×
Q1 25
1.74×
2.57×
Q4 24
1.99×
Q3 24
1.48×
Q2 24
1.95×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons